Q2 FY2026 · ended Jul 4, 2026 · Revenue $12.57M, -7.4% YoY · Filed Aug 18, 2026
Iridex Corp (IRIX) files with the SEC under industry code 3845, Electromedical & Electrotherapeutic Apparatus. In Q2 of fiscal 2026, the quarter ended Jul 4, 2026, it reported revenue of $12.6 million and a net loss of $1.3 million. Free cash flow was $124,000. As of Jul 4, 2026 it held $4.7 million in cash and investments and $218,000 in total debt.
Revenue
$12.57M
-7.4% vs year-ago quarter
Net income
$-1.27M
-27.4% vs year-ago quarter
Operating cash flow
$174,000
+143.8% vs year-ago quarter
Free cash flow
$124,000
+130.2% vs year-ago quarter
EPS
$-0.07
-16.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
17.56M
+3.4% vs year-ago quarter
Net cash
$4.46M
Q2 FY2026
Operating margin
-8.2%
Q2 FY2026
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- IRIX (Nasdaq)
- Fiscal year ends
- January 3
- Incorporated in
- DE
- Headquarters
- Mountain View, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1006045
Other Electromedical & Electrotherapeutic Apparatus companies
- Medtronic plc MDT
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- Axogen, Inc. AXGN
- TransMedics Group, Inc. TMDX
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
All 31 Electromedical & Electrotherapeutic Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jul 4, 2026 |
Q1 FY2026 Apr 4, 2026 |
Q3 FY2025 Sep 27, 2025 |
Q2 FY2025 Jun 28, 2025 |
Q1 FY2025 Mar 29, 2025 |
|---|---|---|---|---|---|
| Revenue | $12.6M | $11.8M | $12.5M | $13.6M | $11.9M |
| Operating income | -$1.0M | -$324,000 | -$1.4M | -$940,000 | -$205,000 |
| Net income | -$1.3M | -$524,000 | -$1.6M | -$994,000 | -$1.7M |
| Diluted EPS | -$0.07 | -$0.03 | -$0.09 | -$0.06 | -$0.10 |
| Operating cash flow | $174,000 | -$1.3M | -$1.2M | -$397,000 | -$1.1M |
| Free cash flow | $124,000 | -$1.4M | -$1.2M | -$410,000 | -$1.2M |
| Total assets | $27.3M | $28.3M | $28.4M | $31.6M | $34.2M |
| Total liabilities | $23.6M | $23.5M | $23.7M | $25.5M | $27.4M |
| Stockholders' equity | $3.6M | $4.7M | $4.7M | $6.1M | $852,000 |
| Cash and investments | $4.7M | $4.6M | $5.6M | $6.8M | $7.2M |
| Total debt | $218,000 | $511,000 | $1.1M | $1.4M | $1.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Sep 2, 2026 | Aug 27, 2026 |
| 10-Q | Quarterly report | Aug 18, 2026 | Jul 4, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 18, 2026 | Aug 18, 2026 |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Jul 16, 2026 | Jul 10, 2026 |
| 8-K |
Current report
Other events
|
Jun 18, 2026 | Jun 12, 2026 |
| 10-Q | Quarterly report | May 19, 2026 | Apr 4, 2026 |
All 1000 Iridex Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.